OVERVIEW
Optimizing Chronic lymphocytic leukemia (CLL) Care: Pharmacist-Led Strategies for Treatment Selection and Toxicity Management is organized by i3 Health.
Dates Available:
September 30, 2025 - September 29, 2026
Statement of Need:
Chronic lymphocytic leukemia (CLL) is a hematologic malignancy characterized by an accumulation of abnormal immature or partially mature B lymphocytes in the blood and bone marrow (Wyatt et al, 2025). The introduction of targeted oral oncolytic therapies has shifted the treatment landscape for CLL, with oral agents now considered the standard first-line therapy. While these therapies provide an efficacious and convenient option for patients, they are associated with a range of toxicities that necessitate careful monitoring. Pharmacists play a crucial role in providing a comprehensive treatment approach to help navigate medication access, monitor safety and patient response, provide patient education, and optimize adherence (Wyatt et al, 2025; Upchurch & Muluneh, 2024). In this podcast, Kelsey Marciano, PharmD, BCOP, Clinical Pharmacy Specialist at UCHealth, will explore pharmacist-led strategies for treatment selection and toxicity management to optimize CLL care.
Learning Objectives:
Upon completion of this activity, participants should be able to:
- Provide informed treatment recommendations as part of the care team to maximize efficacy and minimize intolerance of novel agents in CLL
- Develop evidence-based dose modification and supportive care strategies for managing novel CLL treatment–related toxicities
- Implement pharmacist-led patient education approaches to enhance treatment understanding and promote self-monitoring of adverse events
- Describe the unique role of pharmacists as part of the interprofessional team in enhancing patient care.
ACCREDITATION & CREDITS
Jointly Accredited Provider
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
i3 Health has approved this knowledge-based activity for 0.75 ACPE CE hours. The Universal Activity Number for this activity is JA0008128-0000-25-035-H01-P. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion.
TARGET AUDIENCE
PharmacistOncologistsPractitioners/DoctorsHematologistSPECIALITIES
HematologyOncologyTERMS & CONDITIONS
Disclosure of Relevant Financial Relationships With Ineligible Companies
i3 Health endorses the standards of the ACPE that require everyone in a position to control the content of a CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CPE activity. CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Kelsey Marciano, PharmD, BCOP, has no relevant financial relationships to disclose.
i3 Health has mitigated all relevant financial relationships.
Instructions to Receive Credit
In order to receive credit for this activity, participants must listen to the podcast and submit a completed evaluation at the end of the activity.
Commercial Support
This activity is supported by a medical education grant from BeOne Medicines USA, Inc.
Contact Information
Technical queries or questions regarding activity credit should be directed at support@emedevents.com.
DISCLAIMER
The information provided at this CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Download eMedEvents Mobile App
Track your CE certificates and CME requirements anytime, anywhere.
Quick Links